Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AnHeart Therapeutics

Request full access

Precision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products

Huangpu, ChinaFounded 2018Biotech & Life Sciences

About AnHeart Therapeutics

AnHeart Therapeutics is a clinical-stage biopharmaceutical company that operates globally. The company is primarily focused on the development of innovative precision therapies for cancer patients. Their business model revolves around the research, development, and commercialization of novel drugs, with a recent focus on Taletrectinib, a ROS1 inhibitor. ROS1 inhibitors are a type of drug that blocks certain proteins that can contribute to cancer growth.

AnHeart Therapeutics operates in the biopharmaceutical market, a highly competitive and regulated industry. The company's clients are primarily healthcare providers and patients in need of cancer treatments. The company generates revenue through the successful development and subsequent sale of its drugs to healthcare providers.

Recently, AnHeart Therapeutics has been expanding its leadership in the U.S. and has also secured an exclusive license agreement with Nippon Kayaku for Taletrectinib in Japan. This suggests a strategic focus on both domestic and international growth. Furthermore, the company's new drug application for Taletrectinib has been accepted by China's NMPA, indicating progress in the drug's development and a potential new revenue stream upon successful market launch.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
18
Open positions
None listed
Dealroom signal
65.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Mar 2024 $0 — Nuvation Bio ↗
SERIES BOther financing Dec 2021 $61M $244M Innovent Biologics · Cenova Capital · Sage Partners · Octagon Capital Advisors ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

AnHeart Therapeutics website traffic

Latest recorded traffic for AnHeart Therapeutics is 1.4K monthly website visits, up 16.7% over the last three months. AnHeart Therapeutics's team declined 30.8% over the past year.

Latest monthly visits1.4K 3-month web change+16.7% 1-year team growth-30.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AnHeart Therapeutics in the Huangpu ecosystem

Live from Dealroom

The AnHeart Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Decheng Capital
  • Vertex Ventures China
  • Octagon Capital Advisors
  • Innovent Biologics
  • Cenova Capital
  • Sage Partners
  • Laurion Capital Management

Other known investors1 additional known investor

  • Nuvation Bio
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China64.7%
🇺🇸 United States29.4%
🇭🇰 Hong Kong5.9%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AnHeart Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AnHeart Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.